<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03295734</url>
  </required_header>
  <id_info>
    <nct_id>NCT03295734</nct_id>
  </id_info>
  <brief_title>ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension</brief_title>
  <acronym>ACES</acronym>
  <official_title>ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Research Institute for Metabolism and Diabetes, Advent Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine&#xD;
      if choice of antihypertensive medication influences changes in functional status and other&#xD;
      cardiovascular risk factors among older persons with hypertension when combined with physical&#xD;
      exercise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine&#xD;
      if choice of antihypertensive medication influences changes in functional status and other&#xD;
      cardiovascular risk factors among older persons with hypertension. Functional status,&#xD;
      determined by measures of physical performance, is an important predictor of cardiovascular&#xD;
      outcomes in older adults. Seniors with compromised function experience more CV events, have a&#xD;
      higher risk of undergoing cardiac surgery and higher risk of CVD-related death than&#xD;
      higher-functioning peers. Seniors with hypertension experience accelerated declines in&#xD;
      function, and presently physical exercise is the primary strategy for preventing this&#xD;
      decline. However, functional responses to exercise are highly variable and appear to be&#xD;
      influenced by the type of antihypertensive medication(s) utilized to control blood pressure.&#xD;
      Preliminary evidence suggests that, compared to other first-line antihypertensive agents,&#xD;
      angiotensin converting enzyme (ACE) inhibitors enhance exercise-derived improvements in&#xD;
      functional status among hypertensive seniors. This RCT will test this hypothesis. Sedentary&#xD;
      men and women &gt; 60 years of age with functional limitations and hypertension will be&#xD;
      recruited from two sites to participate in a longitudinal intervention study. Participants&#xD;
      will be randomly assigned to one of three first-line antihypertensive agents: (1) the ACE&#xD;
      inhibitor perindopril, (2) AT1 receptor antagonist losartan, or (3) the thiazide diuretic&#xD;
      hydrochlorothiazide. Note: Participants with a documented history of hypersensitivity to ACE&#xD;
      inhibitors will be randomized 1:1 to one of the two other study drugs. All participants will&#xD;
      also participate in a structured aerobic exercise intervention. The primary aim is to&#xD;
      determine if, compared to losartan and HCTZ, perindopril improves self-paced gait speed. The&#xD;
      secondary aim is to determine the relative effect of perindopril on a) exercise capacity, b)&#xD;
      body mass and composition, and c) circulating indices of cardiovascular risk. This study is&#xD;
      expected to differentiate beneficial effects of three FDA-approved antihypertensive&#xD;
      medications on an emerging cardiovascular risk factor in a clinically-relevant population.&#xD;
      Thus the study has important implications for expeditiously influencing clinical practice&#xD;
      guidelines in the prescription of antihypertensive drugs to millions of Americans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gait speed</measure>
    <time_frame>32 weeks</time_frame>
    <description>Self-paced gait speed over 4m distance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six minute walk test</measure>
    <time_frame>32 weeks</time_frame>
    <description>maximal distance covered over six minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>32 weeks</time_frame>
    <description>% body fat/lean mass collected via dual x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating indices of cardiovascular risk</measure>
    <time_frame>32 weeks</time_frame>
    <description>TNF-α, IL-6, VCAM-1, E-selectin; oxidized LDL; myeloperoxidase</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Hypertension</condition>
  <condition>Aging</condition>
  <condition>Sedentary Lifestyle</condition>
  <arm_group>
    <arm_group_label>Perindopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg qd titrated to 8 mg qd perindopril + aerobic exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg qd titrated to 100 mg qd losartan + aerobic exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Aerobic exercise</intervention_name>
    <description>Twice weekly centered based aerobic exercise + 3/week home-based walking</description>
    <arm_group_label>HCTZ</arm_group_label>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_label>Perindopril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril</intervention_name>
    <description>4 mg qd titrated to 8 mg qd perindopril</description>
    <arm_group_label>Perindopril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>50 mg qd titrated to 100 qd losartan</description>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCTZ</intervention_name>
    <description>12.5 mg qd titrated to 25 qd HCTZ</description>
    <arm_group_label>HCTZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 60 years and older&#xD;
&#xD;
          -  Hypertension - untreated (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg) or treated&#xD;
&#xD;
          -  &gt; 290 seconds needed to complete long-distance corridor walk test&#xD;
&#xD;
          -  Sedentary lifestyle, defined as &lt;150 min/wk of moderate physical activity&#xD;
&#xD;
          -  Willingness to participate in all study procedures, including allowing study team to&#xD;
             communicate with primary care physician regarding changes in antihypertensive&#xD;
             treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BP &gt; 140/90, despite the use of three or more anti-hypertensive drugs&#xD;
&#xD;
          -  SBP &gt; 180 mm Hg or DBP &gt; 110 mm Hg&#xD;
&#xD;
          -  Chronic kidney disease&#xD;
&#xD;
          -  Serum creatinine &gt;2.5 mg/dL in men or &gt;2.0 mg/dL in women&#xD;
&#xD;
          -  Serum potassium outside normal reference range&#xD;
&#xD;
          -  Urinary protein &gt; 1 on dipstick&#xD;
&#xD;
          -  Abnormal liver enzymes (AST, ALT, or alkaline phosphatase &gt; 2.5 times the upper limit&#xD;
             of normal)&#xD;
&#xD;
          -  Severe cardiac disease, including NYHA Class III or IV congestive heart failure,&#xD;
             clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac&#xD;
             defibrillator, or uncontrolled angina&#xD;
&#xD;
          -  Acute myocardial infarction identified by ECG&#xD;
&#xD;
          -  Significant cognitive impairment, defined as a known diagnosis of dementia or a&#xD;
             Mini-Mental State Examination exam score &lt; 24;&#xD;
&#xD;
          -  Simultaneous participation in another intervention trial&#xD;
&#xD;
          -  Known hypersensitivity to ACE inhibitors (exclusion only to perindopril arm; will be&#xD;
             randomized among other two interventions)&#xD;
&#xD;
          -  Any other condition that would preclude participating based upon judgement of PI or&#xD;
             study clinician team&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Buford, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wendy Kohrt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bret Goodpaster, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Research Institute, Advent Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Buford, PhD</last_name>
    <phone>2059963008</phone>
    <email>twbuford@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAB Center for Exercise Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Connor, PhD</last_name>
      <phone>205-996-3005</phone>
      <email>connork@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachary Buxo</last_name>
      <email>ZACHARY.BUXO@CUANSCHUTZ.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susann Nagel</last_name>
      <email>Susann.Buller@AdventHealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Thomas W. Buford</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

